Boston Scientific's Taxus Liberte Coronary stent:
This article was originally published in Clinica
Boston Scientific's paclitaxel-eluting coronary stent, Taxus Liberte, has been approved in Canada. The Company reported that Health Canada's Therapeutic Products Directorate (TPD), the authority that regulates pharmaceutical drugs and medical devices, has approved its use. The Natick, Massachusetts company said it plans to launch the product in Canada immediately. The device is already approved in the EU, and is awaiting clearance in the US.